Praktické lékárenství – 4/2020

www.praktickelekarenstvi.cz e11 MEDICAMENTA NOVA Nová přímá perorální antikoagulancia –nové molekuly ve výzkumu PRAKTICKÉ LÉKÁRENSTVÍ with Extended Prophylaxis. The American Journal of Medicine [online]. 2018 [cit. 2019–02– 25]. DOI: 10.1016/j.amjmed.2018. 08. 024. ISSN 00029343. Dostupné z: https://linkinghub.el- sevier.com/retrieve/pii/S0002934318308520 9. Lekura J, Kalus JS. Overview of betrixaban and its role in clinical practice. American Journal of Health‑System Pharmacy[online]. 2018, 75(15), 1095–1102 [cit. 2019–02–25]. DOI: 10.2146/ajhp170785. ISSN 1079-2082. Dostupné z: https://academic.oup.com/ajhp/artic- le/75/15/1095/5102024 10. Beyer‑Westendorf J, Verhamme P, Bauersachs R. Betrixaban for prevention of ve- nous thromboembolism in acute medically ill patients. European Heart Journal Supple- ments [online]. 2018, 20(suppl E), E16-E22 [cit. 2019–02–25]. DOI: 10.1093/eurheartj/ suy017. ISSN 1520–765X. Dostupné z: https://academic.oup.com/eurheartjsupp/artic- le/20/suppl_E/E16/4993363 11. Iwatsuki Y, Sato T, Moritani Y, Shigenaga T, et al. Biochemical and pharmacological pro- file of darexaban, an oral direct factor Xa inhibitor. European Journal of Pharmacology[onli- ne]. 2011, 673(1–3), 49–55 [cit. 2019–03–19]. DOI: 10.1016/j.ejphar.2011. 10. 009. ISSN 00142999. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0014299911012398 12. Kaku S, Suzuki M, Saitoh M, Funatsu T, et al. Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti‑inhibitor coagulant complex and recombinant factor VIIa. Thrombosis Research [online]. 2013, 131(5), 450–456 [cit. 2019–03–19]. DOI: 10.1016/j.thro- mres.2013. 03. 016. ISSN 00493848. Dostupné z: https://linkinghub.elsevier.com/retrieve/ pii/S0049384813001035 13. Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, et al. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. Biopharmaceutics & Drug Disposition [onli- ne]. 2013, 34(8), 431–441 [cit. 2019–03–19]. DOI: 10.1002/bdd.1858. ISSN 01422782. Dostup- né z: http://doi.wiley.com/10.1002/bdd.1858 14. Hashimoto T, Suzuki K, Kihara Y, et al. Absorption, metabolism and excretion of darexa- ban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica [online]. 2012, 43(6), 534–547 [cit. 2019–03–19]. DOI: 10.3109/00498254.2012.738045. ISSN 0049-8254. Dostupné z: http://www.tandfonline.com/doi/full/10.3109/00498254.2012.738045 15. Kadokura T, Groenendaal D, Heeringa M, Mol R, et al. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. European Journal of Drug Metabolism and Pharmacokinetics [online]. 2014, 39(1), 1–9 [cit. 2019–03–19]. DOI: 10.1007/s13318–013–0141–1. ISSN 0378-7966. Dostupné z: http://link.springer.com/10.1007/ s13318–013–0141–1 16. Kadokura T, Taniuchi Y, Inoue H, Saito M, et al. Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects. Int. Journal of Clinical Pharmacology and Therapeutics [online]. 2013, 51(03), 200–206 [cit. 2019–03– 19]. DOI: 10.5414/CP201804. ISSN 0946-1965. Dostupné z: http://www.dustri.com/article_ response_page.html?artId=10188 & doi=10.5414/CP201804 & L=0 17. Eriksson B I, Turpie AGG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). Journal of Thrombosis and Haemostasis [online]. 2010, 8(4), 714–721 [cit. 2019– 03–20]. DOI: 10.1111/j.1538–7836.2010.03748.x. ISSN 15387933. Dostupné z: http://doi.wiley. com/10.1111/j.1538–7836.2010.03748.x 18. Steg Ph.G, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double‑blind, placebo­ ‑controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. European Heart Journal [online]. 2011, 32(20), 2541–2554 [cit. 2019–03–20]. DOI: 10.1093/eurheartj/ehr334. ISSN 0195–668X. Dostupné z: https://academic.oup.com/eurheartj/article‑lookup/doi/10.1093/eurheartj/ehr334 19. Sakon M, Nakamura M. Darexaban (YM150) prevents venous thromboembolism in Ja- panese patients undergoing major abdominal surgery: Phase III randomized, mechani- cal prophylaxis‑controlled, open‑label study. Thrombosis Research [online]. 2012, 130(3), e52-e59 [cit. 2019–03–20]. DOI: 10.1016/j.thromres.2012. 06. 009. ISSN 00493848. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0049384812002800 20. Gómez‑Outes A, Suárez‑Gea ML, Lecumberri R, Rocha E, at al. New parenteral anticoa- gulants in development. Therapeutic Advances in Cardiovascular Disease[online]. 2011, 5(1), 33–59 [cit. 2019–03–25]. DOI: 10.1177/1753944710387808. ISSN 1753-9447. Dostupné z: http://journals.sagepub.com/doi/10.1177/1753944710387808 21. Hinder M, Frick A, Jordaan P, Hesse G, et al. Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with co- ronary artery disease. Clinical Pharmacology & Therapeutics[online]. 2006, 80(6), 691–702 [cit. 2019–03–25]. DOI: 10.1016/j.clpt.2006. 09. 002. ISSN 00099236. Dostupné z: http://doi. wiley.com/10.1016/j.clpt.2006. 09. 002 22. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, Double‑Blind, Dose‑Ranging Stu- dy of Otamixaban, a Novel, Parenteral, Short‑Acting Direct Factor Xa Inhibitor, in Percuta- neous Coronary Intervention. Circulation [online]. 2007, 115(20), 2642–2651 [cit. 2019–03– 25]. DOI: 10.1161/CIRCULATIONAHA.106.653428. ISSN 0009-7322. Dostupné z: https://www. ahajournals.org/doi/10.1161/CIRCULATIONAHA.106.653428 23. Sabatine MS, EM Antman, Widimsky P, et al. Otamixaban for the treatment of patients with non‑ST‑elevation acute coronary syndromes (SEPIA‑ACS1 TIMI 42): a randomised, double‑blind, active‑controlled, phase 2 trial. The Lancet [online]. 2009, 374(9692), 787–795 [cit. 2019–03–25]. DOI: 10.1016/S0140–6736(09)61454–9. ISSN 01406736. Dostupné z: htt-